KR100980819B1 - The composition comprising complex herbal extract as an active ingredient and the preparation method thereof - Google Patents
The composition comprising complex herbal extract as an active ingredient and the preparation method thereof Download PDFInfo
- Publication number
- KR100980819B1 KR100980819B1 KR1020080034907A KR20080034907A KR100980819B1 KR 100980819 B1 KR100980819 B1 KR 100980819B1 KR 1020080034907 A KR1020080034907 A KR 1020080034907A KR 20080034907 A KR20080034907 A KR 20080034907A KR 100980819 B1 KR100980819 B1 KR 100980819B1
- Authority
- KR
- South Korea
- Prior art keywords
- extraction
- extract
- peony
- health
- essential oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 239000012676 herbal extract Substances 0.000 title claims abstract description 31
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title description 21
- 208000008589 Obesity Diseases 0.000 claims abstract description 29
- 230000036541 health Effects 0.000 claims abstract description 29
- 235000020824 obesity Nutrition 0.000 claims abstract description 29
- 241000736199 Paeonia Species 0.000 claims abstract description 28
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 26
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 26
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 25
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 25
- 229940010454 licorice Drugs 0.000 claims abstract description 25
- 241000287828 Gallus gallus Species 0.000 claims abstract description 24
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 22
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 241000282376 Panthera tigris Species 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 239000000341 volatile oil Substances 0.000 claims description 35
- 239000000284 extract Substances 0.000 claims description 33
- 238000000605 extraction Methods 0.000 claims description 28
- 230000002829 reductive effect Effects 0.000 claims description 21
- 238000010992 reflux Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 241000219061 Rheum Species 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 239000012046 mixed solvent Substances 0.000 claims description 11
- 238000000944 Soxhlet extraction Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000454 talc Substances 0.000 claims description 7
- 229910052623 talc Inorganic materials 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000012454 non-polar solvent Substances 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims 2
- 238000010298 pulverizing process Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 26
- 201000010099 disease Diseases 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 11
- 206010033307 Overweight Diseases 0.000 abstract description 4
- 230000003579 anti-obesity Effects 0.000 abstract description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 2
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 2
- 235000017803 cinnamon Nutrition 0.000 abstract 2
- 238000009472 formulation Methods 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- -1 Rhein ) Chemical compound 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 4
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 235000013985 cinnamic acid Nutrition 0.000 description 4
- 229930016911 cinnamic acid Natural products 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 241000234314 Zingiber Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- HNOSJVWYGXOFRP-UHFFFAOYSA-N Alisol A Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(O)C(C)(C)O)C)CCC21C HNOSJVWYGXOFRP-UHFFFAOYSA-N 0.000 description 2
- NLOAQXKIIGTTRE-JSWHPQHOSA-N Alisol b acetate Chemical compound O([C@@H]1[C@@H](OC(C)=O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C NLOAQXKIIGTTRE-JSWHPQHOSA-N 0.000 description 2
- NLOAQXKIIGTTRE-UHFFFAOYSA-N Alisol-B-Monoacetat Natural products C=12CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CCC=1C(C)CC(OC(C)=O)C1OC1(C)C NLOAQXKIIGTTRE-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 241001522129 Pinellia Species 0.000 description 2
- 108010068736 Pinellia ternata lectin Proteins 0.000 description 2
- 241000219050 Polygonaceae Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 2
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- YOZOWEBNQFOSGC-UHFFFAOYSA-N hexagalloylglucose Natural products Oc1cc(cc(O)c1O)C(=O)OCC2OC(OC(=O)c3cc(O)c(O)c(O)c3)C(OC(=O)c4cc(O)c(O)c(O)c4)C(OC(=O)c5cc(O)c(OC(=O)c6cc(O)c(O)c(O)c6)c(O)c5)C2OC(=O)c7cc(O)c(O)c(O)c7 YOZOWEBNQFOSGC-UHFFFAOYSA-N 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229920002414 procyanidin Polymers 0.000 description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- HNOSJVWYGXOFRP-UNPOXIGHSA-N (5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(2r,4s,5r)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](O)C(C)(C)O)C)CC[C@@]21C HNOSJVWYGXOFRP-UNPOXIGHSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- NIZFPXZQERMCLE-KVFWHIKKSA-N (e)-1-[4-[(2s,3r,4s,5s,6r)-3-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@](O)(CO)CO1)O)O)CO)C(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 NIZFPXZQERMCLE-KVFWHIKKSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- IPQVTOJGNYVQEO-LALZNDFESA-N 9-[(9r)-2-carboxy-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-LALZNDFESA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000206501 Actaea <angiosperm> Species 0.000 description 1
- 241000905376 Actaea dahurica Species 0.000 description 1
- 241000906577 Actaea heracleifolia Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- QQUHMASGPODSIW-UHFFFAOYSA-N Albiflorin Natural products C=1C=CC=CC=1C(=O)OCC12C(=O)OC3(C)CC(O)C1CC32OC1OC(CO)C(O)C(O)C1O QQUHMASGPODSIW-UHFFFAOYSA-N 0.000 description 1
- 241000748223 Alisma Species 0.000 description 1
- 241000209514 Alismataceae Species 0.000 description 1
- WXHUQVMHWUQNTG-UHFFFAOYSA-N Alisol E 24-acetate Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(OC(C)=O)C(C)(C)O)C)CCC21C WXHUQVMHWUQNTG-UHFFFAOYSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- 241000202722 Bupleurum falcatum Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000276534 Cimicifuga simplex Species 0.000 description 1
- 235000015823 Cimicifuga simplex Nutrition 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920000296 Glucogallin Polymers 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- BJYRNIFAMMOVGW-UHFFFAOYSA-N Lindleyin Natural products C1=CC(CCC(=O)C)=CC=C1OC1C(O)C(O)C(O)C(COC(=O)C=2C=C(O)C(O)=C(O)C=2)O1 BJYRNIFAMMOVGW-UHFFFAOYSA-N 0.000 description 1
- BJYRNIFAMMOVGW-OXUVVOBNSA-N Lindleyin Chemical compound C1=CC(CCC(=O)C)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=C(O)C(O)=C(O)C=2)O1 BJYRNIFAMMOVGW-OXUVVOBNSA-N 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000819999 Nymphes Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001522232 Pinellia ternata Species 0.000 description 1
- 208000003141 Plant Poisoning Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 244000171085 Polyporus umbellatus Species 0.000 description 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- RJINLRBSXMOGAQ-KMNHUKDVSA-N [(2r,3r,4s,5r)-6-hydroxy-3,4,5-tris[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate Chemical compound C([C@H]1OC([C@@H]([C@@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)[C@@H]1OC(=O)C=1C=C(O)C(O)=C(O)C=1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RJINLRBSXMOGAQ-KMNHUKDVSA-N 0.000 description 1
- WXHUQVMHWUQNTG-JSWHPQHOSA-N [(3r,4s,6r)-2,4-dihydroxy-6-[(5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-3-oxo-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] acetate Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](OC(C)=O)C(C)(C)O)C)CC[C@@]21C WXHUQVMHWUQNTG-JSWHPQHOSA-N 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- QQUHMASGPODSIW-ICECTASOSA-N albiflorin Chemical compound O([C@@]12C[C@H]3[C@H](O)C[C@@]1(OC(=O)[C@]32COC(=O)C=1C=CC=CC=1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QQUHMASGPODSIW-ICECTASOSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- GDVRUDXLQBVIKP-UHFFFAOYSA-N beta-D-glucogallin Natural products OC1C(O)C(O)C(CO)OC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019726 broiler meat Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- MSUOLNSQHLHDAS-UHFFFAOYSA-N cerebronic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(O)=O MSUOLNSQHLHDAS-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000012721 chromium Nutrition 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 229940104299 cimicifugae rhizoma Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 239000008989 cinnamomi cortex Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- KGHSLXLLBHRMML-VKISENBKSA-N glucogallin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](OC)O[C@H]1OC(=O)C1=CC(O)=C(O)C(O)=C1 KGHSLXLLBHRMML-VKISENBKSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- VMMVZVPAYFZNBM-CMDYPFMGSA-N isoliquiritin apioside Natural products O=C(/C=C/c1ccc(O[C@H]2[C@@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)cc1)c1c(O)cc(O)cc1 VMMVZVPAYFZNBM-CMDYPFMGSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000010729 leg swelling Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000008820 moutan cortex Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 1
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000003523 triterpene group Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 복합생약 추출물을 유효성분으로 함유하는 조성물 및 이의 제조방법에 관한 것으로, 더욱 상세하게는 택사, 대황, 건강, 감초, 육계(계피), 작약, 목단피, 시호, 저령, 반하 및 승마를 포함하는 복합생약 추출물을 유효성분으로 포함하는 조성물은 비만 또는 과체중 대상자의 체질량지수 (BMI)을 감소시킴으로써 항비만 효과를 나타내므로, 상기 조성물은 비만 관련 질환의 예방 및 치료용 약학조성물 또는 건강기능식품으로 유용하게 이용할 수 있다. The present invention relates to a composition and a method for producing the same containing a compound herbal extract as an active ingredient, and more specifically, Taeksa, rhubarb, health, licorice, broiler (cinnamon), peony, bark skin, sea tiger, ghost, half and horse riding Since the composition comprising the complex herbal extract as an active ingredient exhibits an anti-obesity effect by reducing the body mass index (BMI) of an obese or overweight subject, the composition is a pharmaceutical composition or health functional food for the prevention and treatment of obesity-related diseases. It can be usefully used.
택사, 대황, 건강, 감초, 육계(계피), 작약, 목단피, 시호, 저령, 반하, 승마, 비만증 Taxa, rhubarb, health, licorice, broiler (cinnamon), peony, peony, shiho, spirit, half, horse riding, obesity
Description
본 발명은 복합생약 추출물을 유효성분으로 함유하는 비만 관련 질환의 예방 및 치료용 약학조성물 또는 건강기능식품에 관한 것이다.The present invention relates to a pharmaceutical composition or health functional food for the prevention and treatment of obesity-related diseases containing a complex herbal extract as an active ingredient.
[문헌 1] 강진경, 생활습관병의 개념, 대한의사협회지, 3월호. pp188-190 (2004)[1] Kang Jin-kyung, Concept of lifestyle-related diseases, Journal of Korean Medical Association, March. pp188-190 (2004)
[문헌 2] Manson et al., New England J. Med., 333, pp677-685, 1995Manson et al., New England J. Med., 333, pp 677-685, 1995.
[문헌 3] Kopleman P.G., Nature, 404, pp635-643, 2000Document 3: Kopleman P.G., Nature, 404, pp 635-643, 2000
[문헌 4] Must et al., JAMA, 282, pp1523-1529, 1999Document 4 Must et al., JAMA, 282, pp 1523-1529, 1999
[문헌 5] 대한약전 제9개정, 식품의약품안전청고시 제2007-89호, 2007.12.28[Document 5] The 9th Amendment to Korea Pharmacopoeia, Korea Food and Drug Administration Notification No. 2007-89, 2007.12.28
현대인은 산업의 발달로 풍요롭고 편리한 삶을 영위하게 되었다. 그로 인해 높은 수준의 의술이 평균수명의 연장을 이끌어 냈지만, 한 편에서는 생활습관병이라는 새로운 질병이 발생되기도 하였다. 생활습관병이란 우리가 일반적으로 알고 있는 성인병을 2003년 이후로 개칭하여 불리고 있는 질병인데, 고혈압, 알레르기, 비만증, 당뇨, 간경변, 심장질환, 암등이 모두 여기에 속한다. 생활습관병이란 개념을 도입하게 된 이유는, 이들 질병이 식습관, 생활양식 및 환경적요인 등을 개선함으로서 치료가 가능한 질병이기 때문이다 (강진경, 생활습관병의 개념, 대한의사협회지, 3월호, pp188-190, 2004). Modern man has lived a rich and convenient life with the development of industry. As a result, high levels of medicine have led to an increase in life expectancy, but on the other hand, a new disease called lifestyle-related disease has emerged. Lifestyle disease is a disease that has been renamed since 2003, which we commonly know as hypertension, allergy, obesity, diabetes, cirrhosis, heart disease, and cancer. The concept of lifestyle diseases was introduced because these diseases can be treated by improving eating habits, lifestyle, and environmental factors (Kang, Jin Kyung, Concept of lifestyle diseases, Korean Medical Association, March, pp. 188-19). 190, 2004).
비만은 당뇨병, 고혈압, 동맥경화증, 고지혈증, 심혈관 질환, 지방간 등의 성인병과 각종 대사 장애의 원인이 되는 것으로 알려져 있을 뿐만 아니라, 그 자체로도 비만증으로 야기된 지방 조직에 의해 복부에 압박이 가해져 변비와 소화불량, 위장장애 등을 일으키는 경우가 많기 때문에, 세계보건기구(WHO)에서는 비만증을 치료가 필요한 질병이라고 경고한 바 있다.Obesity is known to cause adult diseases such as diabetes mellitus, high blood pressure, arteriosclerosis, hyperlipidemia, cardiovascular disease, fatty liver and various metabolic disorders, as well as constipation caused by pressure on the abdomen by fat tissue caused by obesity In many cases, it causes indigestion, gastrointestinal disorders, and the World Health Organization (WHO) has warned that obesity is a disease that needs treatment.
비만은 소모하는 열량에 비해 과다한 열량을 섭취함으로써 여분의 열량이 체내에 지방의 형태로 축적되어지는 현상을 말한다. 비만은 유전적 영향, 서구화되는 식생활에 의한 환경적인 영향, 스트레스에 의한 심리적인 영향 등 다양한 원인에 의해 유발되어지는 것으로 생각되고 있으나, 아직 그 정확한 원인이나 기작에 관해서는 명확히 정립된 바가 없는 상황이다. 그러나 비만은 비만 그자체가 갖는 문제 점뿐만 아니라, 심혈관계 질환이나 당뇨와 같은 질병의 원인으로도 작용할 수 있기 때문에(Manson et al., New England J. Med., 333, pp677-685, 1995; Kopleman P.G., Nature, 404, pp635-643, 2000; Must et al., JAMA, 282, pp1523-1529, 1999) 전 세계적으로 비만 치료에 많은 관심이 모아지고 있다. Obesity refers to a phenomenon in which excess calories are accumulated in the form of fat in the body by ingesting excessive calories compared to calories consumed. Obesity is thought to be caused by a variety of causes, including genetic influences, environmental effects from westernized diets, and psychological effects from stress, but the exact cause and mechanisms have not been clearly established. . However, because obesity is not only a problem of obesity itself, it can also act as a cause of diseases such as cardiovascular disease and diabetes (Manson et al., New England J. Med., 333, pp677-685, 1995; Kopleman PG, Nature, 404, pp635-643, 2000; Must et al., JAMA, 282, pp1523-1529, 1999). There is much interest in the treatment of obesity worldwide.
비만 치료 방법으로는 칼로리의 이용량을 증가시키는 운동요법, 칼로리 흡수량을 감소시키는 식이요법 및 약물요법 등이 있다. 그러나 바쁜 현대인들에게 운동요법과 식이요법만으로는 적절한 효과를 기대하기 힘들기 때문에 안전한 약물요법을 병행하는 것이 적절하다고 할 수 있다.Obesity treatments include exercise therapy to increase the use of calories, diet and drug therapy to reduce the absorption of calories. However, for busy modern people, exercise therapy and diet alone cannot expect proper effects, so it is appropriate to combine safe drug therapy.
현재까지 알려진 비만 치료제들 중에서 가장 대표적인 약물들로는 제나칼(Xenical™, 로슈제약회사, 스위스), 리덕틸(Reductil™, 애보트사, 미국), 엑소리제(Exolise™, 아토파마, 프랑스) 등이 있으나, 심장질환, 호흡기 질환, 신경계 질환 등의 부작용과 함께 그 효능의 지속성이 낮아, 더욱 효율적인 비만 치료제의 개발이 필요한 실정이다.Among the most known obesity treatments to date, Xenical ™ (Roche Pharmaceuticals, Switzerland), Reductil ™ (Abbott, USA), Exolise ™ (Atopama, France), etc. Along with the side effects such as heart disease, respiratory disease, nervous system diseases, the efficacy is low, the development of a more effective obesity treatment situation is required.
따라서 최근에는 이러한 화학 합성 약물의 부작용을 극복하고자, 인체 안정성이 높아 장기간 사용해도 부작용이 적은 천연소재 약물을 대상으로 광범위한 연구가 수행되고 있다. Therefore, recently, in order to overcome the side effects of such chemical synthetic drugs, extensive research has been conducted on natural drug drugs with high human stability and few side effects even after long-term use.
택사(澤瀉, Alismatis Rhizoma)는 질경이택사 Alisma orientale Juzepzuk (택사과 Alismataceae)의 덩이줄기로서 잔뿌리 및 주피를 제거한 것으로서, 트리텔페노이드(triterpenoid)인 알리솔(alisol) A, B, 알리솔 A 모노아세테이트(alisol A monoacetate), 알리솔 B 모노아세테이트(alisol B monoacetate), 에피알리 솔(epialisol) A 및 소량의 알카로이드(alkaloid)가 함유되어 있고, 이 밖에 정유(푸르푸랄 등), 수지, 아세틸콜린, 레시틴, 아스파라긴을 비롯한 많은 아미노산과 많은 양의 당, 피토스테롤, 피토스테롤린, 기름(팔미틴, 스테아린, 올레인), 많은 녹말(23%), 단백질(7%)이 있으며, 뿌리줄기는 동물실험에서 이뇨작용, 혈압강하 및 간 손상에 예방 작용이 있다. Alismatis Rhizoma is a plantain Alisma As a tuber of orientale Juzepzuk (Texaceae Alismataceae), which removes the roots and bark, it is a triterpenoid alisol A, B, alisol A monoacetate, alisol B monoacetate (alisol B monoacetate), epialisol A and small amounts of alkaloids, and many other amino acids including essential oils (furfural), resins, acetylcholine, lecithin, asparagine and large amounts Sugars, phytosterols, phytosterols, oils (palmitin, stearin, oleine), many starches (23%) and proteins (7%). Root stems are preventive against diuresis, lowering blood pressure and liver damage in animal experiments. have.
대황(大黃, Rhubarb, Rhei Radix et Rhizoma)은 장엽대황(掌葉大黃, Rheum palmatum Linne), 탕구트대황(Rheum tanguticum Maximowicz ex Balf.) 또는 약용대황(藥用大黃, Rheum officinale Baillon, 여뀌과 Polygonaceae)의 뿌리 및 뿌리줄기로서 주피를 제거한 것으로서, 센노시드(Sennoside) A, B, C, D, E, F, 에모딘(Emodin), 크리소파놀(Chrysophanol), 레인(Rhein), 알로에-에모딘(Aloe-emodin), 글리코갈린(Glucogallin), 라폰티신(Rhaponticin), 라탄닌(Rhatanin) Ⅰ, Ⅱ, 린드레인(Lindleyin), 프로시아니딘 b-13-O-갈레이트(Procyanidin b-13-O-gallate) 등의 성분을 함유하며, 사하 작용이 있어서 장위를 세척하고 대사를 촉진시키므로 열성 변비와 복부창만에 손으로 누르면 단단한 것이 촉지되는 증상에 유효하고 이질 초기에 설사가 빈번하고 후중이 있을 때 술을 넣고 달여서 복용한다. 또한 화를 내리는 작용이 있어서 화사가 상염하여 나타난 두통, 눈의 충혈, 인후통, 잇몸이 붓고 아프면서 입 안과 혀가 헐어 발진이 생기고 변비가 있는 증상에 쓰이고 혈열로 인한 코피, 토혈, 각혈에 활용되며, 열독으로 인하여 종기와 등창이 생기고 변비를 수반하는데 유효하며, 맹장염에도 신속한 효과를 나타낸다.Rhubarb (Rhubarb, Rhei Radix et Rhizoma) is Rheum palmatum Linne), Tangut rhubarb ( Rheum tanguticum Maximowicz ex Balf.) or medicinal rhubarb ( Rheum As the root and root stem of the officinale Baillon, Polygonaceae, the skin was removed, Sennoside A, B, C, D, E, F, Emodin, Chrysophanol, Rhein ), Aloe-emodin, Glucogallin, Raponticin, Rhatanin I, II, Lindleyin, Procyanidin b-13-O-gallate ( It contains ingredients such as Procyanidin b-13-O-gallate, and it has lower dead action to clean the intestines and promote metabolism. Frequently and after heavy, add alcohol and take it month after month. In addition, it has an effect of lowering anger, causing headache, redness of eyes, sore throat, swelling and soreness of the gums, swelling in the mouth and tongue, rashes, constipation, and constipation caused by blood fever. It is effective for accompanied by constipation due to heat poisoning, constipation, and rapid effect on appendicitis.
건강(乾薑, Ginger, Zingiberis Rhizoma)은 생강(Zingiber officinale Roscoe, 생강과 Zingiberaceae)의 뿌리줄기를 말린 것으로서, 전분이 전체의 40~60%를 차지하고 소량의 수증기 휘발성, 정유성분, 매운성분, 수지 단백질, 섬유소, 펜토산, 전분 및 무기질 등이 있으며 매운맛 성분인 진제론(Zingerone)과 진제롤(Gingerol), 쇼가올(Shogaol) 등, 향기성분인 시트랄(Citral), 리나룰(Linalool) 등을 함유한다. 위액 분비 촉진과 장관의 연동 작용을 활성화시키므로 소화를 돕고 구토를 가라앉히는 효과를 나타내고, 혈관 운동 중추, 호흡 중추와 심장 흥분 작용이 있어서 혈압을 상승시킴과 동시에 혈액순환을 촉진시키며, 항염증 작용 및 진통 작용이 있고, 인플루엔자균, 콜레라균, 개선균 등에 일정한 억균 작용을 나타낸다.Health (乾薑, Ginger, Zingiberis Rhizoma) is ginger ( Zingiber dried roots of officinale Roscoe, Ginger and Zingiberaceae. Starch occupies 40 ~ 60% of total, small amount of water vapor volatility, essential oils, spicy ingredients, resin protein, fiber, pentosan, starch and minerals. Ingredients such as Zingerone, Gingerol, Shogaol and the like, Citral, Linalool and the like are included. It promotes secretion of gastric juice and activates the peristalsis of the intestinal tract, which helps digestion and calms vomiting.It also has blood vessel movement center, respiratory center and cardiac excitability to increase blood pressure and promote blood circulation, anti-inflammatory action and It has an analgesic effect and exhibits a certain bactericidal effect on influenza bacteria, cholera bacteria, and ameliorating bacteria.
감초(甘草, Licorice, Glycyrrhizae Radix et Rhizoma)는 감초(Glycyrrhiza uralensis Fischer), 광과감초(光果甘草, Glycyrrhiza glabra Linne) 또는 창과감초(脹果甘草, Glycyrrhiza inflata Batal., 콩과 Leguminosae)의 뿌리 및 뿌리줄기로서 그대로 또는 주피를 제거한 것으로서, 글리시리진(glycyrrhizin)(6~10%), 플라보노이드와 아이소(iso), 그리시리진산(glycyrrhizic/glycyrrhizic acid), 사포닌, 쿠마린, 정유, 전분, 파이토스토롤(phytostrol), 탄닌 및 효소, 베투릭산(beturic acid), 올레아놀릭산(oleanolic acid), 리쿠리티제닌(liquiritigenin), 아이소리쿠리티제닌(isoliquiritigenin), 리쿠리틴(liquiritin), 리투라시드(licuraside), 람노리쿠리틴(rhamnoliquiritin) 등을 함유하며, 항균, 항염증, 항알레르기, 항바이러스, 면역기능 항진 등에 효과가 있다. 또한 화중완급, 윤폐지해, 청열해독의 효능의 있으며 포제한 것을 사용하면 비위허약, 노권에 의한 발열, 폐위해수, 동계, 경간을 치료하고 생것은 인후종통, 위궤양, 약물 중독, 식물 중독 을 치료한다. 또한 거담, 변통, 경련진정, 담즙촉진, 해열, 진해, 근육완화, 간보호 및 항암작용이 있다.Licorice, Licorice, Glycyrrhizae Radix et Rhizoma, Glycyrrhiza uralensis Fischer, Glycyrrhiza glabra Linne) or Glycyrrhiza glycyrrhizin (6-10%), flavonoids and iso, glycyrrhizic / glycyrrhizic acid, saponin as intact or bark removed as intula or root stem of inflata Batal. , Coumarin, essential oils, starch, phytostrol, tannins and enzymes, beturic acid, oleanolic acid, liquiritigenin, isoliquiritigenin, liqueurin ( liquiritin), lituraside (licuraside), rhamnoliquiritin (rhamnoliquiritin), etc., and is effective in antimicrobial, anti-inflammatory, anti-allergic, antiviral, immune function enhancement. In addition, it can be used to treat injuries, gastric ulcers, drug intoxication, and plant poisoning. do. It also has expectoration, constipation, cramping, bile stimulation, antipyretic, antitussive, muscle relaxant, hepatoprotective and anticancer activity.
육계(肉桂, Cinnamomi Cortex)는 육계(肉桂, Cinnamomum cassia Presl., 녹나무과 Lauraceae)의 줄기껍질로서 그대로 또는 주피를 다소 제거한 것으로서, 휘발성 정유 성분이 1~2% 함유되어 있으며, 주성분은 시나믹알데하이드(cinnamic aldehyde)가 75~90%이고, 그 밖에 점액질, 탄닌(tannin) 등이 함유되어 있으며, 정유 중에는 펠란드렌(phellandrene), 유제놀(eugenol), 메틸유제놀(methyleugenol)이 함유되어 있다. 중추 신경을 억제하므로 진정ㆍ진통ㆍ해열 작용이 있고, 심장과 관상 동맥의 혈류량 촉진, 항방사능 작용 및 백혈구 수 증가작용, 피부진균의 억제 작용이 있으며, 특히 개선균을 억제하는 작용이 있다.The broiler (Cinnamomi Cortex) is the broiler ( Cinnamomum) cassia Presl., the stem bark of Camphoraceae Lauraceae), as it is or with a slightly removed bark, contains 1 ~ 2% of volatile essential oils, 75 ~ 90% of cinnamic aldehyde, and other mucus , Tannin, etc. are contained, and essential oils include phellandrene, eugenol, and methyleugenol. Since it suppresses the central nerve, it has a sedative, analgesic, and antipyretic effect, promotes blood flow in the heart and coronary arteries, anti-radioactivity and white blood cell count, and inhibits skin fungi.
작약(芍藥, Paeoniae Radix)은 작약(Paeonia lactiflora Pallas) 또는 기타동속근연식물 (작약과, Paeoniaceae)의 뿌리로서, 모노텔펜(Monoterpene)인 알비플로린(Albiflorin), 파에온니플로린(Paeoniflorin), 옥시파에온니플로린(Oxypaeoniflorin), 벤졸파에온니플로린(Benzoylpaeoniflorin)과 벤조익산(Benzoic acid) 및 탄닌류인 테트라갈로일글루코스(Tetragalloylglucose), 펜타갈로일글루코스(Pentagalloylglucose), 헥사갈로일글루코스(Hexagalloylglucose) 등을 함유한다. 간을 부드럽게 하고 통증을 멎게 하는 작용을 하며 피가 부족해서 안색이 누렇고 월경시 복통이 있는 증상과 식은땀을 흘리며 손발에 경련이 있는 증상 및 두통에도 좋으며 간질, 각종 경련증상, 천식, 신장결석, 치질 등에도 매우 좋다.Pee (Peoniae Radix) is Paeonia As roots of lactiflora Pallas or other related plant species (Peaceaceae, Paeoniaceae), the monotelpenes (Albiflorin), Paeoniflorin, Oxypaeoniflorin, Benzolpaonniflorin ( Benzoylpaeoniflorin), benzoic acid (Benzoic acid) and tannins, such as tetragalloylglucose, pentagalloylglucose (Pentagalloylglucose) and hexagalloylglucose (Hexagalloylglucose). It works to soften the liver and stop pain, and the lack of blood causes complex yellowing, menstrual abdominal pain, cold sweating, convulsions in the hands and feet, headaches, epilepsy, various cramps, asthma, kidney stones, Very good for hemorrhoids.
목단피(牡丹皮, Moutan Cortex)는 목단(Paeonia suffruticosa Andrews, 작약과 Paeoniaceae)의 뿌리껍질로서, 파에놀-글루코시드(Paenol-glucoside), 파에놀-람노글루코시드(Paeonol-rhamnoglucoside)를 함유하고 있고 저장중 배당체의 분해에 의하여 파에놀(Paeonol)의 가향이 있는 결정이 석출된다. 심과 간과 신장에 작용하여 생리불순이나 생리통, 멍든 것이나 토혈, 코피, 반점이 나타나는 증상에 사용하며, 특히 이 약은 출혈을 멈추게 하지만 뭉치지 않게 하고, 피를 잘 돌게 해주면서 넘치지 않도록 하는 특징을 가지고 있다. 또한 진정과 최면, 진통작용, 혈압 강하작용, 다리 부종을 억제하는 작용, 항균작용이 있다.Moutan Cortex ( Paeonia) suffruticosa Andrews, Peony and Paeoniaceae), which contains Paenol-glucoside, Paeonol-rhamnoglucoside, and the decomposition of glycosides during storage Preferred crystals are precipitated. It acts on the heart, liver, and kidneys to help with menstrual irregularities, cramps, bruises, hemorrhages, nosebleeds, and spots. In particular, this drug stops bleeding but does not clump and keeps blood flowing. . It also has sedation and hypnosis, analgesic action, lowering blood pressure, inhibiting leg swelling, and antibacterial action.
시호(柴胡, Bupleuri Radix)는 시호(Bupleurum falcatum Linne) 또는 그 변종 (산형과 Umbelliferae)의 뿌리로서, 사이코사포닌(saikosaponin) a, c, d, e, 알파-스피나스테롤, 스티그마스테롤, ℓ-아노말린(ℓ-Anomalin) 등을 함유하며, 간장의 기능을 조정하는 작용이 있어서 해열, 해독, 진통, 강장제로 쓰이고, 소화기 질환, 호흡기 질환, 순환기 질환 등에 한열이 왕래하고 가슴이 답답한데 쓰이며, 민간요법으로는 감기에 뿌리 말린 것을 달여 먹는다.Shiple, Bupleuri Radix, Bupleurum falcatum Linne) or its varieties (mountain and Umbelliferae), containing saikosaponin a, c, d, e, alpha-spinasterol, stigmasterol, l-anomalin, etc. It is used to adjust the function of the liver, fever, detoxification, analgesic, tonic, is used for digestive diseases, respiratory diseases, circulatory diseases, etc. .
저령(猪, Chuling, Polyporus)은 저령(猪, Polyporus umbellatus Fries, 구멍장이버섯과 Polyporaceae)의 균핵으로서, 에르고스테롤(Ergosterol), 2-하이드록시테트라코사닉산(2-Hydroxytetracosanic acid), 글럭타르(Gluctar), 비오틴(Biotin), 스테롤(sterol), ergosta-4,6,8(14), 22-tetraen-3-one, 비티온(bithion) 등을 함유하며, 이뇨, 소종, 청열에 효과가 있고, 항종양, 항균, 보체 및 마크로파아지(macrophage) 활성이 있다.Jeoryeong (猪, Chuling, Polyporus) is jeoryeong (猪, Polyporus umbellatus Fries, fungus of Polygonaceae and Polyporaceae, Ergosterol, 2-Hydroxytetracosanic acid, Gluctar, Biotin, Sterol, ergosta It contains -4,6,8 (14), 22-tetraen-3-one, bithion, etc., and it is effective in diuresis, swelling and clearing, antitumor, antibacterial, complement and macrophage. There is activity.
반하(半夏, Pinelliae Tuber)는 반하(Pinellia ternata Breitenbach, 천남성과 Araceae)의 덩이줄기로 주피를 완전히 제거한 것으로서, 베타-시토스테롤(beta-Sitosterol), 켐페스테롤(Campesterol), 아피제닌-6-C-베타-D-갈락토피라노사이드(Apigenin-6-C-beta-D-galactopyranoside), 콜린( Choline), 다우코스테롤(Daucosterol), 피넬리아 렉틴(Pinellia lectin), 피넬리아 폴리사카라이드(Pinellia polysaccaride) PT-F-2-1, 피넬린(Pinellin) 등을 함유하며, 유독성분으로 거담, 진해작용이 있으며 약물달인 물은 구토를 멈추게 하고, 규폐증 예방에 유효성을 나타낸다. Pinelliae Tuber is Pinellia ternata Breitenbach, a tuber of Chronicles and Araceae, completely removes the bark, beta-Sitosterol, Campesterol, Apigenin-6-C-beta-D-galactopyranoside (Apigenin) -6-C-beta-D-galactopyranoside, Choline, Dacosterol, Pinellia lectin, Pinellia polysaccaride PT-F-2-1 , Pinellin (Pinellin), etc., as a toxic component has an expectorant, antitussive action and drug decoction stops vomiting, and is effective in preventing silicosis.
승마(升麻, Cimicifugae Rhizoma)는 승마(Cimicifuga heracleifolia Komarov), 촛대승마(Cimicifuga simplex Wormskjord), 눈빛승마( Cimicifuga dahurica Maximowicz) 또는 황새승마(Cimicifuga foetida Linne, 미나리아재비과 Ranunculaceae)의 뿌리줄기로서, 베타-카로틴, 시미시퓨진(cimicifugenin), 포모노네틴, 갈릭산, 식물 스테롤, 살리실산, 타닌산, 타닌, 칼슘, 크롬, 철, 마그네슘, 망간, 인, 칼륨, 셀레늄, 규소, 아연, 비타민 B1, B2, B3, C 등을 함유하며, 천연 식물성 에스트로겐(Phyto-Estrogens)은 폐경기 때 일어나는 여러가지 장애와 불편을 상당히 감소시키는 효과가 있다. 혈압과 콜레스테롤을 낮추고 점액 생성을 막으며 심혈관과 혈액순환 장애를 막고 분만과 출산에 도움을 준다. 또한 폐경기 증상과 허리에 통증이 생기는 생리통에 효과가 있으며 뱀에 물렸을 때와 관절염에 쓴다.Riding (升麻, Cimicifugae Rhizoma) riding (Cimicifuga heracleifolia Komarov), Candlestick Horseriding ( Cimicifuga simplex Wormskjord), Snow Horseriding ( Cimicifuga dahurica Maximowicz) or Stork Horse ( Cimicifuga) As root stem of foetida Linne, Ranunculaceae, beta-carotene, cimicifugenin, pomononetin, gallic acid, plant sterol, salicylic acid, tannic acid, tannin, calcium, chromium, iron, magnesium, manganese, phosphorus Contains potassium, selenium, silicon, zinc, vitamins B 1 , B 2 , B 3 , and C. Natural phytoestrogens (Phyto-Estrogens) have the effect of significantly reducing various disorders and discomforts during menopause. Lowers blood pressure and cholesterol, prevents mucus production, prevents cardiovascular and blood circulation disorders, and helps with delivery and childbirth. It is also effective for menstrual cramps with menopausal symptoms and back pain. It is used for snake bites and arthritis.
본 발명자들은 복용하기 편리하며, 체내에서 흡수가 신속하게 이루어져 약효 및 치료효과를 극대화 시킬 수 있는 택사, 대황, 건강, 감초, 육계, 작약, 목단피, 시호, 저령, 반하 및 승마를 포함하는 복합생약 추출물의 제조방법 및 이들 유효성분으로 함유하는 조성물의 항비만 효과를 확인하여 본 발명을 완성하였다.The inventors of the present invention are convenient to take, compound absorption including talc, rhubarb, health, licorice, broiler, peony, bark skin, shiho, nymph, halves and horse riding that can be quickly absorbed in the body to maximize the efficacy and therapeutic effect The present invention was completed by confirming the anti-obesity effect of the preparation method of the extract and the composition containing these active ingredients.
상기 목적을 달성하기 위하여, 본 발명은 택사, 대황, 건강, 감초, 육계, 작약, 목단피, 시호, 저령, 반하 및 승마를 포함하는 복합생약 추출물을 유효성분으로 함유하는 비만 관련 질환의 예방 및 치료용 약학조성물을 제공한다.In order to achieve the above object, the present invention is to prevent and treat obesity-related diseases containing complex herbal extracts including taxa, rhubarb, health, licorice, broiler, peony, bark skin, sea tiger, ghost, half and horse riding as an active ingredient Provide a pharmaceutical composition.
또한, 본 발명은 택사, 대황, 건강, 감초, 육계, 작약, 목단피, 시호, 저령, 반하 및 승마를 포함하는 복합생약 추출물을 유효성분으로 함유하는 비만 관련 질환의 예방 및 개선용 건강기능식품을 제공한다.In addition, the present invention provides a dietary supplement for the prevention and improvement of obesity-related diseases, including complex herbal extracts including taxa, rhubarb, health, licorice, broiler, peony, bark skin, shiho, ghost, half and horse riding as an active ingredient to provide.
상기 비만 관련 질환에는 비만증, 당뇨병, 고혈압, 동맥경화증, 고지혈증, 심혈관 질환 또는 지방간, 바람직하게는 비만증을 포함한다.Such obesity-related diseases include obesity, diabetes, hypertension, arteriosclerosis, hyperlipidemia, cardiovascular disease or fatty liver, preferably obesity.
본원에서 정의되는 복합생약 추출물은 택사, 대황, 건강, 감초, 육계, 작약, 목단피, 시호, 저령, 반하 및 승마의 혼합중량비(%)가 1~10 : 1~5 : 1~5 : 1~5 : 1~5 : 1~5 : 1~5 : 1~10 : 1~10 : 1~5 : 1~5, 바람직하게는 1~4 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~4 : 1~4 : 1~2 : 1~2로 구성됨을 포함한다.Complex herbal extracts defined herein is a mixed weight ratio (%) of talc, rhubarb, health, licorice, broiler, peony, bark skin, shiho, ghost, halves and horse riding 1-10: 1-5: 1-5: 1 ~ 5: 1-5: 1-5: 1-5: 1-10: 1-10: 1-5: 1-5, preferably 1-4: 1-2: 1-2: 1: 2: 1 ~ 2: 1 ~ 2: 1 ~ 2: 1 ~ 4: 1 ~ 4: 1 ~ 2: 1 ~ 2
본원에서 정의되는 복합생약 추출물은 정제수를 포함한 물, 탄소수 1 내지 6의 저급알코올 또는 이들의 혼합용매로 부터 선택된 용매, 바람직하게는 물, 에탄 올 또는 이들의 혼합용매를 포함한다.The complex herbal extract as defined herein includes a solvent selected from water, including purified water, a lower alcohol having 1 to 6 carbon atoms or a mixed solvent thereof, preferably water, ethanol or a mixed solvent thereof.
본원에서 정의되는 복합생약 추출물은 액제, 현탁제, 정제, 캡슐제 또는 주사제, 바람직하게는 액제의 형태로 제조하는 것을 포함한다. The combined herbal extract as defined herein includes the preparation in the form of a liquid, suspension, tablet, capsule or injection, preferably a liquid.
또한, 본 발명은 택사, 대황, 건강, 감초, 육계, 작약, 목단피, 시호, 저령, 반하 및 승마를 포함하는 복합생약 추출물의 제조방법을 제공한다.In addition, the present invention provides a method for producing a complex herbal extract including taxa, rhubarb, health, licorice, broiler, peony, bark skin, shiho, ghost, half and horse riding.
본원에서 정의되는 제조방법은 정유성분 및 비정유성분을 나누어서 추출하는 방법 또는 정유성분을 포함한 전체를 추출하는 방법, 정유성분을 추출하고 비정유성분을 순차적으로 추출하는 방법, 바람직하게는 정유성분 및 비정유성분을 별개로 나누어서 추출하는 방법을 포함한다. The manufacturing method defined herein is a method for extracting the essential oil and non-essential components separately or a method for extracting the whole including the essential oil components, a method for extracting the essential oil components and extracting the non-essential components, preferably essential oil components and non-essential components And extracting them separately.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 복합생약 추출물은 하나의 구현예로서 하기와 같이 제조될 수 있다. 택사, 대황, 건강, 감초, 육계, 작약, 목단피, 시호, 저령, 반하 및 승마의 중량배합비가 1~10 : 1~5 : 1~5 : 1~5 : 1~5 : 1~5 : 1~5 : 1~10 : 1~10 : 1~5 : 1~5의 중량부, 바람직하게는 1~4 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~4 : 1~4 : 1~2 : 1~2의 중량부로 혼합한 후 절단하거나 분말화하는 제 1단계; 이 생약분말 중량의 5배 내지 10배, 바람직하게는 8배 (w/v%)의 약염기성 수용액, 물, 탄소수 1 내지 6의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물, 에탄올 또는 이들의 혼합용매, 더욱 바람직하게는 물 또는 30 내지 100% 에탄올로 10℃ 내지 120℃에서 1시간 내지 7시간, 바람직하게는 3시간 내지 6시간 동안 환류추출법, 초임계추출법, 속슬렛추출법, 열수추출법, 냉각추출법 또는 초음파추출법, 바람직하게는 환류추출법, 초임계추출법 또는 속슬렛추출법으로 추출하는 제 2단계; 이를 저온 감압 농축시키는 제 3단계를 포함하는 제조방법을 통해 본 발명의 복합생약 추출물을 수득할 수 있다.Complex herbal extract of the present invention can be prepared as one embodiment as follows. Weight mix ratio of taxa, rhubarb, health, licorice, broiler, peony, bark skin, sea tiger, ghost, halves and horseback riding 1-10: 1-5: 1-5: 1-5: 1-5: 1-5: 1 5: 1 to 10: 1 to 10: 1 to 5: 1 to 5 parts by weight , preferably 1 to 4: 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 2: 1 to 4: 1 to 4: 1 to 2: 1 to 2 parts by weight after mixing or cutting to powder; A solvent selected from 5 to 10 times, preferably 8 times (w / v%), weakly basic aqueous solution of water, lower alcohols having 1 to 6 carbon atoms or a mixed solvent thereof, preferably water, Reflux extraction, supercritical extraction, soxhlet extraction for 1 hour to 7 hours, preferably 3 hours to 6 hours at 10 ° C. to 120 ° C. with ethanol or a mixed solvent thereof, more preferably water or 30 to 100% ethanol. A second step of extracting by hot water extraction, cooling extraction or ultrasonic extraction, preferably by reflux extraction, supercritical extraction or soxhlet extraction; The compound herbal extract of the present invention can be obtained through a manufacturing method comprising a third step of concentrating this under reduced pressure.
본 발명의 복합생약 추출물은 또다른 구현예로서 하기와 같이 제조될 수 있다. 택사, 대황, 건강, 감초, 육계, 작약, 목단피, 시호, 저령, 반하 및 승마의 중량배합비가 1~10 : 1~5 : 1~5 : 1~5 : 1~5 : 1~5 : 1~5 : 1~10 : 1~10 : 1~5 : 1~5의 중량부, 바람직하게는 1~4 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~2 : 1~4 : 1~4 : 1~2 : 1~2의 중량부로 혼합한 후 절단하거나 분말화하는 제 1단계; 이 생약분말 중량의 5배 내지 10배, 바람직하게는 8배 (w/v%)의 물, 탄소수 1 내지 6의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물, 에탄올 또는 이들의 혼합용매, 더욱 바람직하게는 물 또는 30 내지 100% 에탄올로 10℃ 내지 120℃에서 1시간 내지 7시간, 바람직하게는 3시간 내지 6시간 동안 비극성용매로는 탄소수 1 내지 6의 저급 알칸족 및 에테르류 등, 바람직하게는 헥산 또는 시클로헥산으로 추출하는 정유추출법, 초임계추출법, 또는 속슬렛추출법으로 추출하여 정유성분만을 수득하는 제 2단계; 제 2단계에서 정유성분을 제한 잔사에 물, 탄소수 1 내지 6의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물, 에탄올 또는 이들의 혼합용매, 더욱 바람직하게는 물 또는 30 내지 100% 에탄올로 10℃ 내지 120℃에서 1시간 내지 7시간, 바람직하게는 3시간 내지 6시간 동안 환류추출법, 초임계추출법, 속슬렛추출법, 열수추출법, 냉각추출법 또는 초음파추출법, 바람직하게는 환류추출법, 초임계추출법 또는 속슬렛추출법으로 추출하는 제 3단계; 상기 단계에서 제조된 추출물을 저온 감압 농축시키는 정유성분 외 비정유성분을 수득하는 제 4단계; 이를 제 2단계의 정유성분과 합하는 제 5단계를 포함하는 제조방법을 통해 본 발명의 복합생약 추출물을 수득할 수 있다.Complex herbal extract of the present invention can be prepared as another embodiment as follows. Weight mix ratio of taxa, rhubarb, health, licorice, broiler, peony, bark skin, sea tiger, ghost, halves and horseback riding 1-10: 1-5: 1-5: 1-5: 1-5: 1-5: 1 5: 1 to 10: 1 to 10: 1 to 5: 1 to 5 parts by weight , preferably 1 to 4: 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 2: 1 to 4: 1 to 4: 1 to 2: 1 to 2 parts by weight after mixing or cutting to powder; A solvent selected from 5 to 10 times, preferably 8 times (w / v%) of water, a lower alcohol having 1 to 6 carbon atoms, or a mixed solvent thereof, preferably water, ethanol or their Lower alkanes and ethers having 1 to 6 carbon atoms as mixed solvents, more preferably water or nonpolar solvents for 1 hour to 7 hours, preferably 3 hours to 6 hours at 10 ° C. to 120 ° C. with 30 to 100% ethanol. A second step of extracting by essential oil extraction, supercritical extraction, or Soxhlet extraction, preferably extracted with hexane or cyclohexane, to obtain only essential oil components; In the second step, the essential oil component is added to the limited residue in a solvent selected from water, a lower alcohol having 1 to 6 carbon atoms or a mixed solvent thereof, preferably water, ethanol or a mixed solvent thereof, more preferably water or 30 to 100%. Reflux extraction, supercritical extraction, soxhlet extraction, hydrothermal extraction, cooling extraction or ultrasonic extraction, preferably reflux extraction, ultrace for 1 hour to 7 hours, preferably 3 hours to 6 hours at 10 ℃ to 120 ℃ with ethanol Extracting by a critical extraction method or a soxhlet extraction method; A fourth step of obtaining an essential oil component other than an essential oil component which is concentrated under a reduced pressure under reduced pressure of the extract prepared in the above step; The compound herbal extract of the present invention can be obtained through the preparation method comprising the fifth step of combining this with the essential oil component of the second step.
본 발명은 상기의 제조방법으로 얻어진 복합생약 추출물을 유효성분으로 함유하는 비만 관련 질환의 예방 및 치료용 약학조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of obesity-related diseases containing the complex herbal extract obtained by the above method as an active ingredient.
또한, 본 발명은 상기의 제조방법으로 얻어진 복합생약 추출물을 유효성분으로 함유하는 비만 관련 질환의 예방 및 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for the prevention and improvement of obesity-related diseases containing the complex herbal extract obtained by the above method as an active ingredient.
본 발명의 복합생약 추출물을 함유하는 비만 관련 질환의 예방 및 치료를 위한 약학조성물은, 조성물 총 중량에 대하여 상기 복합생약 추출물을 0.1 내지 100 중량% 포함한다.The pharmaceutical composition for the prevention and treatment of obesity-related diseases containing the multi-drug extract of the present invention comprises 0.1 to 100% by weight of the multi-drug extract based on the total weight of the composition.
본 발명의 복합생약 추출물을 함유하는 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. The pharmaceutical composition containing the complex herbal extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
본 발명의 복합생약 추출물을 함유하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 화합물을 함유하는 조성물에 함유될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프 로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스 (sucrose) 또는 락토오스 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골 (macrogol), 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Pharmaceutical compositions containing the complex herbal extract of the present invention may be in the form of powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories, and sterile injectable solutions, respectively, according to a conventional method. Can be formulated and used. Carriers, excipients and diluents which may be contained in the composition containing the compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose, etc. Or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 복합생약 추출물 사용량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으나, 0.1 내지 100 mg/kg을 일일 1회 내지 수회 투여할 수 있다. 또한 그 투여량은 투여경로, 질병의 정도, 성별, 체중, 나이 등에 따라서 증감될 수 있다. 따라서 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The amount of the combined herbal extract of the present invention may vary depending on the age, sex, and weight of the patient, but may be administered once to several times daily from 0.1 to 100 mg / kg. The dosage may also be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.
상기 약학조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 (intracerebroventricular) 주사에 의해 투여될 수 있다.The pharmaceutical composition may be administered to various mammals such as mice, mice, livestock, humans, and the like. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
본 발명은 상기 복합생약 추출물을 유효성분으로 포함하는 비만 관련 질환의 예방 및 개선용 건강기능식품을 제공한다. 이를 첨가할 수 있는 식품으로는 각종 식품류, 분말, 과립, 정제, 캡슐, 시럽제, 음료, 껌, 차, 비타민 복합제, 건강기능성 식품류 등이 있다.The present invention provides a health functional food for the prevention and improvement of obesity-related diseases comprising the complex herbal extract as an active ingredient. Foods to which it may be added include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods.
또한, 비만 관련 질환의 예방 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이때 식품 또는 음료 중의 복합생약 추출물의 양은 전체 식품 중량의 0.01 내지 50 중량%로 가할 수 있으며, 건강 기능성 음료 조성물은 100 ml 기준으로 0.02 내지 5 g, 바람직하게는 0.01 내지 1 g의 비율로 가할 수 있다.It may also be added to foods or beverages for the purpose of preventing obesity-related diseases. At this time, the amount of the compound herbal extract in the food or beverage may be added in 0.01 to 50% by weight of the total food weight, the health functional beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.01 to 1 g based on 100 ml. have.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 복합생약 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에르트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제 (타우마틴, 스테비아 추출물) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml 당 일반적으로 약 1 내지 20 g, 바람직하게는 약 3 내지 15 g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except the compound herbal extract as an essential ingredient in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients, as in general beverages. Can be. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tautin, stevia extract) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 3-15 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 복합생약 추출물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 복합생약 추출물은 천연 과일주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하지는 않지만 본 발명의 복합생약 추출물 100 중량부 당 0 내지 약 50 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the complex herbal extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, such as flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid And salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the complex herbal extract of the present invention may contain a flesh for preparing natural fruit juice and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not so critical, but is usually selected in the range of 0 to about 50 parts by weight per 100 parts by weight of the complex herbal extract of the present invention.
본 발명은 복합생약 추출물을 유효성분으로 함유하는 조성물 및 이의 제조방법에 관한 것으로, 상세하게는 택사, 대황, 건강, 감초, 육계, 작약, 목단피, 시호, 저령, 반하 및 승마를 포함하는 복합생약 추출물을 유효성분으로 함유하는 조성물이 비만 또는 과체중 대상자의 체질량지수 (BMI)을 감소시킴으로써 항비만 효과를 나타내므로, 상기 조성물은 비만 관련 질환의 예방 및 치료용 약학조성물 또는 건강기능식품으로 유용하게 이용될 수 있다.The present invention relates to a composition containing the extract of the compound herbal as an active ingredient, and a method for producing the same, and in particular, a compound containing a taxa, rhubarb, health, licorice, broiler, peony, peony, shiho, herb, half and horseback Since the composition containing the extract as an active ingredient exhibits an anti-obesity effect by reducing the body mass index (BMI) of obese or overweight subjects, the composition is useful as a pharmaceutical composition or health functional food for the prevention and treatment of obesity-related diseases. Can be.
이하 본 발명을 실시예 및 실험예에 의해 상세히 설명한다. 단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 이에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by Examples and Experimental Examples. However, the following Examples and Experimental Examples are merely illustrative of the present invention, but the content of the present invention is not limited thereto.
실시예Example 1. 건조분말의 제조 1. Preparation of dry powder
택사 286g, 대황 143g, 건강 143g, 감초 143g, 육계 143g, 작약 143g, 목단피 143g, 시호 286g, 저령 286g, 반하 143g 및 승마 143g (국일무약, 수입산)를 절단하거나 분말화하여 하기 실험의 시료 (이하 “HPJ"이라 명명함)로 사용하였다.Taxi 286g, rhubarb 143g, health 143g, licorice 143g, broiler 143g, peony 143g, bark skin 143g, sea hoe 286g, age 286g, half 143g and horseback riding 143g (Japanese national fragrance, imported), or cut and powdered "HPJ").
실시예Example 2. 복합생약 2. Combined Herbal Medicine 열수Hydrothermal 추출물의 제조 Preparation of Extract
2-1. 환류추출법2-1. Reflux Extraction Method
상기 실시예 1에서 수득한 HPJ 50.0 g을 물 400 ml에 넣어 충분히 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 60-70 Brix 될 때까지 저온 감압 농축하여 복합생약 열수 추출물 11.45 g (22.9%, 이하 'HPJ-H1'이라 명명함)을 얻었다.50.0 g of HPJ obtained in Example 1 was poured into 400 ml of water, followed by swelling sufficiently, followed by reflux extraction in an extractor for 3-6 hours (x3), and the extract obtained by filtration was concentrated under reduced pressure until 60-70 Brix. To obtain a compound herbal hydrothermal extract 11.45 g (22.9%, hereinafter referred to as 'HPJ-H1').
2-2. 정유추출법2-2. Essential oil extraction
상기 실시예 1에서 수득한 HPJ 500.0 g 중 정유성분을 포함한 약재를 정유 추출장치 (경서기계, COSMOS 660, 한국)에 넣은 후 물 5000 ml를 넣어 충분히 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류추출하여(x3) 정유 정량기에 있는 정유성 분을 취하고, 정유 정량기를 제거하고 추출기에 있는 나머지 잔사에 물 5000 ml를 넣은 다음, 3-6시간 동안 추출기에서 환류 추출한 후, 여과하여 얻은 추출액을 저온 감압 농축하고 먼저 취한 정유성분과 합하여 60-70 Brix의 복합생약 열수 추출물 113.5 g (22.7%, 이하 'HPJ-H2'라 명명함)를 얻었다.The medicine containing the essential oil component of 500.0 g of HPJ obtained in Example 1 was placed in an essential oil extraction device (Gyeongseo machine, COSMOS 660, Korea), and then swelled sufficiently with 5000 ml of water, and then refluxed in the extractor for 3-6 hours. Extract (x3) the essential oil in the refinery quantifier, remove the essential oil quantifier, add 5000 ml of water to the remaining residue in the extractor, extract it under reflux in the extractor for 3-6 hours, and filter the resulting extract at low temperature Concentrated and combined with the essential oil components first to obtain 113.5 g (22.7%, hereinafter referred to as 'HPJ-H2') of 60-70 Brix complex herbal hot water extract.
2-3. 초임계추출법2-3. Supercritical extraction
상기 실시예 1에서 수득한 HPJ 50.0 g을 탄산가스와 에탄올 3 ml/min로 초임계 추출장치 (JASCO, 일본)를 이용하여 정유 성분을 취하고, HPJ 잔사에 물 400 ml를 가해서 충분시간 동안 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 60-70 Brix가 될 때까지 저온 감압 농축하고 먼저 취한 정유성분과 합하여 복합생약 열수 추출물 11.25 g (22.5%, 이하 ‘HPJ-H3'이라 명명함)를 얻었다.50.0 g of HPJ obtained in Example 1 was extracted with essential oil using a supercritical extractor (JASCO, Japan) at 3 ml / min of carbon dioxide and ethanol, and 400 ml of water was added to the HPJ residue to swell for a sufficient time. Next, the mixture was refluxed in an extractor for 3-6 hours (x3), and the extract obtained by filtration was concentrated under reduced pressure until 60-70 Brix, and combined with the essential oil component taken first, 11.25 g (22.5%) Named 'HPJ-H3').
2-4. 속슬렛추출법12-4. Soxhlet Extraction Method 1
상기 실시예 1에서 수득한 HPJ 50.0 g을 속슬렛 추출장치(Soxhlet apparatus, 대신과학, AP1240, 한국)를 이용하여 물 400 ml에 넣어 충분히 팽윤시킨 다음, 3-6시간 동안, 추출기에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 60-70 Brix가 될 때까지 저온 감압 농축하여 복합생약 열수 추출물 11.50 g (23.0%, 이하 ‘HPJ-H4'이라 명명함)를 얻었다.The HPJ 50.0 g obtained in Example 1 was added to 400 ml of water using a Soxhlet apparatus (Daeshin Science, AP1240, Korea), swelled sufficiently, and then extracted under reflux in an extractor for 3-6 hours. (x3), the extract obtained by filtration was concentrated under reduced pressure at 60-70 Brix to obtain 11.50 g (23.0%, hereinafter referred to as 'HPJ-H4') of the compound herbal hot water extract.
2-5. 속슬렛추출법2 2-5. Soxhlet Extraction Method 2
상기 실시예 1에서 수득한 HPJ 50.0 g 중 정유성분을 포함한 약재를 속슬렛 추출장치(Soxhlet apparatus)에 넣은 후 물 200 ml를 넣어 충분히 팽윤시킨 다음, 3-6시간 동안 속슬렛 추출장치(Soxhlet apparatus)에서 환류 추출하여(x3) 방냉한 후 여과하여 얻은 추출액을 저온 감압 농축(추출액의 25%가 될 때까지)한 다음, 추출 농축액을 비극성 용매인 헥산 100ml을 3회 추출한 후 농축하여 정유 성분을 취하고, 여액과 잔사를 추출기에 넣고 나머지 약재와 물 400 ml를 넣어 충분히 팽윤시킨 다음, 3-6시간 동안 속슬렛 추출장치(Soxhlet apparatus)에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 저온 감압 농축하고 먼저 취한 정유 성분과 합하여 60-70 Brix의 복합생약 열수 추출물 11.45 g (22.9%, 이하 ‘HPJ-H5'이라 명명함)를 얻었다.The medicine containing the essential oil component of the HPJ 50.0 g obtained in Example 1 was added to a Soxhlet apparatus (Soxhlet apparatus) and then swelled enough to put 200 ml of water, Soxhlet apparatus (Soxhlet apparatus) for 3-6 hours The mixture was extracted at reflux (x3), cooled to room temperature, filtered, and concentrated under reduced pressure (until 25% of the extract was extracted). The extracted concentrate was extracted three times with 100 ml of hexane, which is a nonpolar solvent, and concentrated. The filtrate and the residue were put in an extractor, and the remaining medicinal herbs and 400 ml of water were swelled sufficiently, followed by reflux extraction in a Soxhlet apparatus for 3-6 hours (x3), and the extract was filtered under reduced pressure. Concentrated and combined with the essential oil components first obtained 11.45 g (22.9%, hereinafter referred to as 'HPJ-H5') of 60-70 Brix complex herbal hot water extract.
실시예Example 3. 복합생약 30% 에탄올 추출물의 제조 3. Preparation of the compound herbal 30% ethanol extract
3-1. 환류추출법13-1. Reflux Extraction Method 1
상기 실시예 1에서 수득한 HPJ 50.0 g을 30% 수포화 에탄올 혼합용액 400 ml에 넣어 충분히 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 60-70 Brix가 될 때까지 저온 감압 농축하여 복합생약 30% 에탄올 추출물 9.55 g (19.1%, 이하 ‘HPJ-E1'이라 명명함)를 얻었다.50.0 g of HPJ obtained in Example 1 was added to 400 ml of a 30% saturated ethanol mixed solution, followed by sufficient swelling, followed by reflux extraction in an extractor for 3-6 hours (x3), and the extract obtained by filtration was 60-70 Brix The mixture was concentrated under reduced pressure at low temperature until it was obtained 9.55 g of a compound herbal 30% ethanol extract (19.1%, hereinafter referred to as 'HPJ-E1').
3-2. 환류추출법23-2. Reflux Extraction Method 2
상기 실시예 1에서 수득한 HPJ 50.0 g 중 정유성분을 포함한 약재를 30% 수포화 에탄올 혼합용액 200 ml에 넣어 충분히 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류 추출하여(x3) 방냉한 후 여과하여 얻은 추출액을 저온 감압 농축(추출액의 25%가 될 때까지)한 다음, 추출농축액을 비극성 용매인 헥산 100ml을 3회 추출 한 후 농축하여 정유 성분을 취하고, 여액과 잔사를 추출기에 넣고 나머지 약재에 30% 수포화 에탄올 혼합용액 400 ml에 넣어 충분히 팽윤시킨 다음 추출기에서 3-6시간 환류 추출한 후(x3), 여과하여 얻은 추출액을 저온 감압 농축하고 먼저 취한 정유 성분과 합하여 60-70 Brix의 복합생약 30% 에탄올 추출물 11.45 g (22.9%, 이하 ‘HPJ-E2'이라 명명함)를 얻었다.The medicine containing the essential oil component in 50.0 g of HPJ obtained in Example 1 was swelled sufficiently in 200 ml of 30% saturated ethanol mixed solution, followed by extraction under reflux in an extractor for 3-6 hours (x3), and then cooled and filtered. The extract was concentrated under reduced pressure (until 25% of the extract), and the extract was extracted three times with 100 ml of hexane, a non-polar solvent, and concentrated to take the essential oil components. The filtrate and residue were placed in an extractor and the remaining herbs were extracted. The mixture was poured into 400 ml of 30% saturated ethanol mixed solution, swelled sufficiently, extracted under reflux for 3-6 hours in the extractor (x3), concentrated under reduced pressure under reduced pressure, and combined with the essential oil components taken first. 11.45 g (22.9%, hereinafter referred to as 'HPJ-E2') of crude 30% ethanol extract was obtained.
실시예Example 4. 복합생약 70% 에탄올 추출물의 제조 4. Preparation of Complex Herbal 70% Ethanol Extract
상기 실시예 1에서 수득한 HPJ 50.0 g을 70% 수포화 에탄올 혼합용액 400 ml에 넣어 충분히 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 60-70 Brix가 될 때까지 저온 감압 농축하여 복합생약 70% 에탄올 추출물 12.05 g (24.1%, 이하 ‘HPJ-E3'이라 명명함)를 얻었다.50.0 g of HPJ obtained in Example 1 was poured into 400 ml of a 70% saturated ethanol mixed solution, sufficiently swelled, refluxed in an extractor for 3-6 hours (x3), and the extract was filtered to obtain 60-70 Brix The mixture was concentrated under reduced pressure at low temperature until 12.05 g (24.1%, hereinafter referred to as 'HPJ-E3') of the crude herbal 70% ethanol extract was obtained.
실시예Example 5. 복합생약 100% 에탄올 추출물의 제조 5. Preparation of Compound Herbal 100% Ethanol Extract
5-1. 환류추출법5-1. Reflux Extraction Method
상기 실시예 1에서 수득한 HPJ 50.0 g을 100% 에탄올 400 ml에 넣어 충분히 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 60-70 Brix가 될 때까지 저온 감압 농축하여 복합생약 100% 에탄올 추출물 9.60 g (19.2%, 이하 ‘HPJ-E4'이라 명명함)를 얻었다.50.0 g of HPJ obtained in Example 1 was poured into 400 ml of 100% ethanol and sufficiently swelled, followed by reflux extraction in an extractor for 3-6 hours (x3), followed by filtration until the extract was 60-70 Brix. Concentration under reduced pressure under reduced pressure yielded 9.60 g (19.2%, hereinafter referred to as 'HPJ-E4') compound 100% ethanol extract.
5-2. 초임계추출법5-2. Supercritical extraction
상기 실시예 1에서 수득한 HPJ 50.0 g을 탄산가스와 에탄올 3 ml/min로 초임 계 추출장치 (JASCO, 일본)를 이용하여 정유 성분을 취하고, HPJ 잔사에 100% 수포화 에탄올 혼합용액 400 ml를 가해서 충분시간 동안 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 60-70 Brix가 될 때까지 저온 감압 농축하여 복합생약 100% 에탄올 추출물 11.35 g (22.7%, 이하 ‘HPJ-E5'이라 명명함)를 얻었다.50.0 g of HPJ obtained in Example 1 was taken with essential oil components using a supercritical extractor (JASCO, Japan) at 3 ml / min of carbon dioxide and ethanol, and 400 ml of 100% saturated ethanol mixed solution was added to the HPJ residue. After swelling for enough time, the mixture was refluxed in an extractor for 3-6 hours (x3), and the extract obtained by filtration was concentrated under reduced pressure until it reached 60-70 Brix, followed by 11.35 g (22.7%) of a compound herbal 100% ethanol extract. , Hereinafter referred to as 'HPJ-E5').
실시예Example 6. 복합생약 6. Combined Herbal Medicine 약염기성Weakly basic 추출물의 제조 Preparation of Extract
탄산수소나트륨(NaHCO3) 0.05g을 물 400 ml에 미리 가하여 넣고 상기 실시예 1에서 수득한 HPJ 50.0 g을 넣어 12~24시간 동안 팽윤시킨 다음, 3-6시간 동안 추출기에서 환류 추출한 후(x3), 여과하여 얻은 추출액을 60-70 Brix가 될 때까지 저온 감압 농축하여 복합생약 약염기성 추출물 11.95 g (23.9%, 이하 ‘HPJ-WB'이라 명명함)를 얻었다.0.05 g of sodium bicarbonate (NaHCO 3 ) was previously added to 400 ml of water, and 50.0 g of HPJ obtained in Example 1 was added thereto, followed by swelling for 12 to 24 hours, followed by extraction under reflux for 3-6 hours (x3). ), The extract obtained by filtration was concentrated under reduced pressure until it became 60-70 Brix to obtain 11.95 g of a compound herbal weakly basic extract (23.9%, hereinafter referred to as 'HPJ-WB').
본 발명의 복합생약 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.It describes an example of the formulation of a composition comprising a complex herbal extract of the present invention, the present invention is not intended to limit it, but is intended to explain in detail only.
제제예Formulation example 1. One. 액제의Liquid 제조 Produce
HPJ-H1 459 ㎎HPJ-H1 459 mg
소르빈산칼륨 10 ㎎10 mg potassium sorbate
폴리소르베이트 80 0.04 ml0.04 ml of polysorbate 80
교미제 적량Copulation
착향제 적량Flavoring Agent
정제수 적량Purified water
상기의 성분을 혼합하고, 통상의 액제 제조방법에 따라서 액제를 제조한다.The above components are mixed to prepare a liquid according to a conventional liquid preparation method.
제제예Formulation example 2. 2. 현탁제의Suspension 제조 Produce
HPJ-H1 459 ㎎HPJ-H1 459 mg
히드록시에칠셀룰로오스 30 ㎎Hydroxyethyl Cellulose 30 mg
한천 30 ㎎Agar 30 mg
D-소르비톨 70% 1.6 g1.6 g of D-sorbitol 70%
착향제 적량Flavoring Agent
정제수 적량Purified water
상기의 성분을 혼합하고, 통상의 현탁제 제조방법에 따라서 현탁제를 제조한다.The above components are mixed to prepare a suspending agent according to a conventional suspending agent production method.
제제예Formulation example 3. 정제의 제조 3. Preparation of Tablets
HPJ-H1 459 ㎎HPJ-H1 459 mg
전분 100 ㎎Starch 100 mg
스테아린산 마그네슘 적량Magnesium stearate proper amount
코팅기제 적량Coating base amount
상기의 성분을 혼합하고, 통상의 정제 제조방법에 따라서 정제를 제조한다.The above components are mixed and tablets are prepared according to a conventional tablet production method.
제제예Formulation example 4. 캡슐제의 제조 4. Preparation of Capsules
HPJ-H1 459 ㎎HPJ-H1 459 mg
전분 100 ㎎Starch 100 mg
탈크 1 ㎎Talc 1 mg
스테아린산 마그네슘 적량Magnesium stearate proper amount
상기의 성분을 혼합하고, 통상의 캡슐제의 제조방법에 따라서 캡슐제를 제조한다.The above ingredients are mixed to produce a capsule according to a conventional method for producing a capsule.
제제예Formulation example 5. 주사제의 제조 5. Preparation of Injectables
HPJ-E1 459 mg HPJ-E1 459 mg
만니톨 180 mgMannitol 180 mg
Na2HPO4·12H2O 26 mg Na 2 HPO 4 · 12H 2 O 26 mg
주사용 멸균 증류수 적 량Sterile distilled water for injection
통상 주사제의 제조방법에 따라 1 바이알당 (20 ml) 상기의 성분 함량으로 제조한다.Usually, it is prepared in the above-described content of ingredients per one vial (20 ml) according to the preparation method of the injection.
제제예Formulation example 6. 건강식품의 제조 6. Manufacture of health food
HPJ-E3 1000 mgHPJ-E3 1000 mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 mg Vitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 mgVitamin C 10 mg
비오틴 10 ㎍10 μg biotin
니코틴산아미드 1.7 mgNicotinamide 1.7 mg
엽산 50 ㎍50 μg folic acid
판토텐산 칼슘 0.5 mgCalcium Pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture
황산제1철 1.75 mgFerrous Sulfate 1.75 mg
산화아연 0.82 mgZinc Oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mg15 mg potassium monophosphate
제2인산칼슘 55 mgDicalcium Phosphate 55 mg
구연산칼륨 90 mgPotassium Citrate 90 mg
탄산칼슘 100 mgCalcium Carbonate 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강기능식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixtures is a composition that is relatively suitable for the health functional food, the composition is mixed in a preferred embodiment, but the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health functional food manufacturing method. Then, the granules may be prepared and used for preparing the nutraceutical composition according to a conventional method.
제제예Formulation example 7. 건강 음료의 제조 7. Manufacture of health drinks
HPJ-E2 1000 mg HPJ-E2 1000 mg
구연산 1000 mgCitric acid 1000 mg
올리고당 100 g100 g oligosaccharides
매실농축액 2 gPlum concentrate 2 g
타우린 1 g1 g of taurine
정제수 전체 900 ml900 ml of purified water whole
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.After mixing the above components according to the conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored Used to prepare the healthy beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조 성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the blending ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
실험예Experimental Example 1. One. 안정성시험Stability test
상기 제제예 1 및 제제예 3에서 제조한 제품의 안정성 시험을 위해 식품의약품안전청 고시 제2007-14호(2007. 3. 19) 의약품 등의 안정성시험기준 및 대한약전 제9개정(식품의약품안전청고시 제2007-89호, 2007. 12. 28) 일반시험법중 미생물 한도 시험법에 따라 하기와 같이 실험하였다. In order to test the stability of the products prepared in Formulation Examples 1 and 3, Notification of Food and Drug Administration No. 2007-14 (March 19, 2007) 2007-89, 2007. 12. 28) According to the microbial limit test method of the general test method was tested as follows.
40℃에서 6개월 동안 상대습도 75%의 가속조건에서 보관하여 각 시험 시기별로 검체를 채취하여 시험하였다. 함량 시험방법은 자외부흡광광도계 (측정파장 250 nm)를 장착한 액체크로마토그래프법에 따라 C18 칼럼을 사용하여 용매구배법을 이용하여 감초 중 글리시리진산, 육계 중 신남산, 작약 및 목단피 중 총 패오니플로린을 동시 정량하는 방법을 사용하였다.Samples were collected at each test period by storing them at an accelerated condition of 75% relative humidity for 6 months at 40 ° C. Content test method was liquid chromatograph method equipped with an ultraviolet absorption photometer (measured wavelength 250 nm) using a solvent gradient method using a C18 column, glycyrrhizin acid in licorice, cinnamic acid in broiler meat, peony and total plaque in bark skin. A method of co-quantitating oniflorin was used.
실험결과, 하기 표 1 및 표 2에 나타난 바와 같이, 제제예 1의 육계 중 신남산, 감초 중 글리시리진산, 작약 및 목단피 중 총 패오니플로린의 함량 변화가 거의 없고, pH 및 미생물시험 항목에서도 안정하며, 제제예 3의 육계 중 신남산, 감초 중 글리시리진산, 작약 및 목단피 중 총 패오니플로린의 함량이 변화가 거의 없고, 붕해도 및 미생물시험 항목에서도 안정하여 약제학적으로 매우 안정한 제제임을 확인할 수 있었다.As a result of the experiment, as shown in Table 1 and Table 2, there is little change in the content of cinnamic acid, glycyrizinic acid in licorice, total peonyflorin in peony and bark skin of the broiler of Formulation Example 1, stable in pH and microbial test items In addition, the content of cinnamic acid in the broilers of Formulation Example 3, glycyrrhizin acid in licorice, peony and bark skin is almost unchanged, stable in disintegration and microbial test items, and can be confirmed to be a very pharmaceutically stable formulation. there was.
생
물beauty
student
water
량box
Amount
(패오니플로린)Peony / Peel
(Phaeniflorin)
생
물beauty
student
water
실험예 2. 비교용출 시험Experimental Example 2. Comparative Dissolution Test
상기 실시예 1에서 수득한 HPJ(산제) 및 제제예 2에서 제조한 제품의 유효 생리활성 성분의 추출 효율성 시험을 측정하기 위해 대한약전에 기재된 용출시험법에 따라 하기와 같이 실험하였다.In order to measure the extraction efficiency test of the effective bioactive components of the HPJ (powder) obtained in Example 1 and the product prepared in Formulation Example 2, the following experiment was carried out according to the dissolution test method described in the Korean Pharmacopoeia.
HPJ(산제) 및 제제예 2를 각각 1회 복용량씩 넣고 위액 산성조건 (대한약전 9개정 붕해시험법, 제1액, pH 1.2)에서 용출액 500 ml를 사용하여 10분, 20분, 30분, 60분, 120분 동안 교반하며, 각 시간대별로 검액을 각각 취하여 상기 실험예 1의 안정성 시험방법에 준하여 유효생리활성 성분 함량을 비교 시험하였다. 계산은 산제 및 추출물의 각각의 기준 함량치에 대한 백분율로 환산하였다.HPJ (powder) and Formulation Example 2 were added in one dose each, using gastric eluent 500 ml for 10 minutes, 20 minutes, 30 minutes, under gastric acidic conditions (9 tablets disintegration test method, first solution, pH 1.2). The mixture was stirred for 60 minutes and 120 minutes, and the sample solution was taken at each time slot, and the effective bioactive component content was compared according to the stability test method of Experimental Example 1. Calculations were converted into percentages for each reference content of powder and extract.
실험결과, 하기 표 3에 나타난 바와 같이 육계 중 신남산, 감초 중 글리시리진산, 작약 및 목단피 중 총 패오니플로린의 함량이 HPJ에 비해, 상대적으로 제제예 2에서 유효성분의 추출효율이 10분대부터 아주 높게 나타남을 확인할 수 있었다.As a result, as shown in Table 3, the content of cinnamic acid in broilers, glycyrrhizin acid in licorice, total peonyflorin in peony and bark skin is relatively higher than that of HPJ, and the extraction efficiency of the active ingredient in Formula 2 is 10 minutes. It was confirmed that it appeared very high.
(패오니플로린)Peony / Peel
(Phaeniflorin)
(글리시리진산)licorice
Glyceric acid
(패오니플로린)Peony / Peel
(Phaeniflorin)
(글리시리진산)licorice
Glyceric acid
실험예 3. 임상시험Experimental Example 3. Clinical Trial
상기 제제예 1에서 제조한 제품의 비만증 및 과체중 대상자에 대한 간이 임상시험을 위해 하기와 같이 실험하였다.The following experiment was conducted for a simple clinical trial of obese and overweight subjects of the product prepared in Preparation Example 1.
제제예 1을 1일 3회, 1회 30 ml씩 총 20명의 실험대상자들, 남자 12명, 여자 8명에게 2-3개월 동안 복용하게 하였다. 단, 15세 이하는 1/2 감량 복용하게 하였다. 실험 전, 후의 비만도를 체질량지수 (BMI, Body Mass Index)를 지표로 하여 하기 수학식 1에 따라 측정하였다. 체질량지수(BMI) 지수가 25 이상이면 비만, 체질량지수(BMI)가 23 이상이면 과체중으로 분류하였다.Formulation Example 1 was administered to 20 subjects, 12 males, and 8 females three times a day, 30 ml once a day for 2-3 months. However, 15 years of age or younger was to lose 1/2. Obesity before and after the experiment was measured according to Equation 1 using the body mass index (BMI) as an index. If the body mass index (BMI) index is 25 or more, it was classified as obese, and if the body mass index (BMI) was 23 or more, it was classified as overweight.
실험결과, 하기 표 4에 나타난 바와 같이 간이임상시험 대상자 모두 개인차가 있으나 실험 전에 비하여 체질량지수(BMI) 수치가 약 1.05±0.75 감소됨을 확인할 수 있었다.As a result, as shown in Table 4 below, all of the subjects of the short-term clinical trial had individual differences, but the body mass index (BMI) value was confirmed to be reduced by about 1.05 ± 0.75 compared to before the experiment.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080034907A KR100980819B1 (en) | 2008-04-15 | 2008-04-15 | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080034907A KR100980819B1 (en) | 2008-04-15 | 2008-04-15 | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090109446A KR20090109446A (en) | 2009-10-20 |
KR100980819B1 true KR100980819B1 (en) | 2010-09-10 |
Family
ID=41552737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080034907A KR100980819B1 (en) | 2008-04-15 | 2008-04-15 | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100980819B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101303693B1 (en) * | 2011-06-30 | 2013-09-04 | 한국식품연구원 | Compositions for Improving Lipid Metabolism Disease, Menopause Disease or Cardiovascular Disease |
KR101360168B1 (en) | 2012-04-20 | 2014-02-11 | 대한민국 | Optimal extraction methods for the tocochromanol in soybean |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101013940B1 (en) * | 2009-11-12 | 2011-02-14 | 주식회사 자연인 | The method that extract aromatic substance from chinese herb medicine |
KR101289018B1 (en) * | 2011-09-30 | 2013-07-24 | 세명대학교 산학협력단 | Composition of antiobese comprising Cinnamomi Cortex and food comprising thereof |
KR101361536B1 (en) * | 2011-12-27 | 2014-02-13 | 세명대학교 산학협력단 | Isolation method of Antiobese Constituents from Yukeuigambitang |
JP2014091706A (en) * | 2012-11-02 | 2014-05-19 | Kao Corp | Glp-1 secretion promoter |
KR101498179B1 (en) * | 2013-12-03 | 2015-03-12 | 대전대학교 산학협력단 | Manufacturing method for Yongdamsagantanggagambang For the treatment of hyperlipidemia, Yongdamsagantanggagambang For the treatment of hyperlipidemia and composition produced by the same |
KR102130044B1 (en) | 2018-03-23 | 2020-07-03 | 한국한의학연구원 | A composition for preventing or treating obesity comprising natural mixture extracts |
WO2019182227A1 (en) * | 2018-03-23 | 2019-09-26 | 한국한의학연구원 | Composition, comprising natural combined extract, for prevention or treatment of obesity |
KR101866915B1 (en) * | 2018-04-12 | 2018-06-12 | 조형권 | Manufacturing method for extracts granule of oriental herb medicine materials for improving constipation and extracts granule manufactured by the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030012709A (en) * | 2001-08-04 | 2003-02-12 | 양상철 | a making method for dietetic food |
KR20070034561A (en) * | 2007-03-08 | 2007-03-28 | 유홍구 | Thought Medicine |
-
2008
- 2008-04-15 KR KR1020080034907A patent/KR100980819B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030012709A (en) * | 2001-08-04 | 2003-02-12 | 양상철 | a making method for dietetic food |
KR20070034561A (en) * | 2007-03-08 | 2007-03-28 | 유홍구 | Thought Medicine |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101303693B1 (en) * | 2011-06-30 | 2013-09-04 | 한국식품연구원 | Compositions for Improving Lipid Metabolism Disease, Menopause Disease or Cardiovascular Disease |
KR101360168B1 (en) | 2012-04-20 | 2014-02-11 | 대한민국 | Optimal extraction methods for the tocochromanol in soybean |
Also Published As
Publication number | Publication date |
---|---|
KR20090109446A (en) | 2009-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100980819B1 (en) | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof | |
Sellami et al. | Herbal medicine for sports: a review | |
CN1964730B (en) | Herbal compositions for prevention and treatment rheumatic and inflammatory diseases and method of preparing the same | |
Kulkarni et al. | Indian gooseberry (Emblica officinalis): Complete pharmacognosy review | |
US8597695B1 (en) | Herbal combinations for treatment of a skin condition | |
EP3076984B1 (en) | Herbal combinations for treatment of a skin condition | |
KR20080050794A (en) | Composition comprising complex crude drug extract (mst) for preventing and treating obesity | |
CN104524146A (en) | Traditional Chinese medicine composition for prevention and adjuvant treatment of hypertensive, hyperlipidemia and hyperglycemia and application of traditional Chinese medicine composition | |
US20160136218A1 (en) | Molecular and Herbal Combinations for Disease Therapy | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
KR100522579B1 (en) | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress | |
Alam et al. | Therapeutic use of Withania somnifera | |
KR20050004950A (en) | Composition comprising the herbal complex extract for prevention and treatment of menorrhalgia and dysmenorrhea | |
KR100522176B1 (en) | Composition for improving male sexual function | |
KR101776793B1 (en) | Composition for Treatment of Lung Cancer and Functional Food Comprising Extract of Olibanum | |
KR20180043763A (en) | Composition for Treatment of Lung Cancer Comprising Extract of Crassirhizomae Rhizoma | |
KR20060030575A (en) | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism | |
KR101814132B1 (en) | Composition for Treatment of Lung Cancer and Functional Food Comprising Extract of Patriniae Radix | |
CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
KR20040041235A (en) | Pharmaceutical composition comprising the water-soluble component of kupferkies and the extract of crude drug effective to treat neuronal paralysis and neuralgia | |
KR20120111765A (en) | Composition for treatment of lung cancer and beauty expenses composition comprising extract of amomi cardamomi fructus | |
KR102070796B1 (en) | Composition for preventing, alleviating or treating ovarian dysfunction comprising extract of medicinal herb mixture as effective component | |
Nesari et al. | Fenugreek (Methika): Traditional Wisdom and Research Evidences | |
KR20210157522A (en) | Composition for preventing, ameliorating or treating diabetic nepropathy comprising bangpungtongseongsan extract as effective component | |
CN118303621A (en) | Food composition for improving appearance and glaring and tonifying qi and blood and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130827 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140901 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150507 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160627 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170519 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180503 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190619 Year of fee payment: 10 |